Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Update

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the target of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 36,700 shares, a decrease of 22.2% from the August 15th total of 47,200 shares. Currently, 2.8% of the shares of the stock are short sold. Based on an average daily volume of 45,600 shares, the days-to-cover ratio is presently 0.8 days.

Hedge Funds Weigh In On Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Armistice Capital LLC bought a new stake in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 75,000 shares of the company’s stock, valued at approximately $262,000. Armistice Capital LLC owned approximately 7.97% of Avenue Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 17.34% of the company’s stock.

Avenue Therapeutics Stock Down 0.7 %

Avenue Therapeutics stock traded down $0.02 during trading hours on Monday, hitting $2.79. 20,397 shares of the company traded hands, compared to its average volume of 62,279. Avenue Therapeutics has a 1-year low of $2.25 and a 1-year high of $64.27. The firm has a market cap of $2.63 million, a P/E ratio of -0.35 and a beta of -0.17. The firm’s 50-day simple moving average is $2.88 and its two-hundred day simple moving average is $5.57.

Avenue Therapeutics (NASDAQ:ATXI) last posted its quarterly earnings data on Friday, August 9th. The company reported ($6.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($5.38).

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.